We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Portable Test Detects SARS-CoV-2 Antibodies in People Who Have Tested Positive for COVID-19

By LabMedica International staff writers
Posted on 31 Mar 2021
Print article
Image: New Portable Test Detects SARS-CoV-2 Antibodies in People Who Have Tested Positive for COVID-19 (Photo courtesy of University of Oxford)
Image: New Portable Test Detects SARS-CoV-2 Antibodies in People Who Have Tested Positive for COVID-19 (Photo courtesy of University of Oxford)
A new easy-to-produce test quickly detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

An international research team led by scientists at the University of Oxford (Oxford, UK) has developed a portable test for antibodies that fight the novel coronavirus that causes COVID-19. The test, which spots the presence of virus-fighting antibodies rather than a coronavirus infection, can be adapted to work on blood from a finger prick - making it quick and easy to use. The research team, which includes scientists from Taiwan, India, Thailand and France, as well as UK university and NHS researchers, trialed the test on patients with COVID-19, but now hope to adapt it to identify those who have successfully generated antibodies after a vaccine, versus those who may need a booster.

The scientists also hope that the large-scale use of their tests might help researchers and policy-makers track levels of protective immunity in the community. Antibodies are large proteins that lock onto and help the body’s immune system fight off disease-causing organisms, such as the novel coronavirus that causes COVID-19. Both infection with the virus and vaccines can generate antibodies. There are already several commercial tests, which can detect whether someone has antibodies against the novel coronavirus, but these tests are expensive and usually need a central laboratory to analyze them. This is especially a problem in low-income countries.

The test relies on linking a part of the viral spike protein to the surface of red blood cells. When antibodies to the virus are present they create a clump of red blood cells. This clump is big enough to be seen by eye. The test also does not require any special equipment or take a long time to show the results, and is accurate. It correctly identifies coronavirus spike protein antibodies 90% of the time, with less than a 1% false positive rate. The researchers note that they can be adapted to work using blood from a finger prick sample. They now plan to use this very simple test in future trials to see if it can identify those who are protected against COVID-19 from those who may need a booster vaccination.

“Our test is very cheap to produce, so we are using existing funding from charitable donations to offer 10 million tests for research purposes to countries that cannot support very high-tech solutions,” said study lead Professor Alain Townsend from the MRC Human Immunology Unit at Oxford University.

Related Links:
University of Oxford

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more